PFE 화이자 · Pfizer, Inc.

내부자 3명 장내 매수, 52주 신고가, 배당수익률 5.8%. 11/3 실적 발표 예정.

종가$29.85
시가총액$1,686억
업종헬스케어
다음 실적 발표2026-11-03
PER38.9배
매출 성장(최근 4분기)-0.2%
애널리스트 순상향률-4.5%
목표가 상승여력-2.0%
공매도 거래 비중46%
1년 수익률+29%

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, s

2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다

같은 업종 종목